Preethi Marri, M.D.
Pediatric Hematology and OncologyAssistant Professor of PediatricsSpecialty: Pediatrics, Cancer CareEducation
- Medical School: SVS Medical College-NTR University of Health Sciences | Andhra Pradesh, India
- Internship: William Beaumont Hospital | Royal Oak, MI
Languages
- English
Locations
- Pediatric SpecialistsClinic is located in Strada Patient Care Center
Clinical Trials
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Treatment for Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study
Treatment for Pediatric Oncology - Neuroblastoma
AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Treatment for Germ Cell Tumor (GCT)
ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Treatment for Pediatric Oncology- Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
AALL1731 A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)
Treatment for Pediatric Oncology- Localized B-Lymphoblastic Lymphoma (B-LLy)
AALL1732 - A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Treatment for Pediatric Oncology- Newly Diagnosed High-Risk B-ALL
S1826 - A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Treatment for - Classical Hodgkin Lymphoma
| ACNS1721: A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations |
Treatment for Pediatric Oncology - Brain tumor
ACNS1422-A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Treatment for Pediatric Oncology - Medulloblastoma
AAML1831 - A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Treatment for newly diagnoses myeloid leukemia
NCI COVID-19 in Cancer Patients, NCCAPS Study
Observational for Oncology with COVID-19
| AALL1631 - International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones |
Treatment for Pediatric Oncology - lymphoblastic leukemia
AALL1821 - A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse
Treatment for Pediatric Oncology- B-ALL
ALTE11C2 - Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
Observational study to learn about effects of dexrazoxane hydrochloride
ALTE2031 - StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
Childhood cancer survivors who do not meet physical activity guidelines
ARST1921 - A Safety, Pharmacokinetic and Efficacy Study of a γ-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
Desmoid Tumors that cannot be removed by surgery